{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:16:17Z","timestamp":1791472577637,"version":"4.3.4"},"reference-count":175,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.beha.2025.101600","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:20:36Z","timestamp":1740615636000},"page":"101600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytokines in hematopoietic cell transplantation and related cellular therapies"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-4040","authenticated-orcid":false,"given":"Abdul-Hamid","family":"Bazarbachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2025.101600_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.aca.2014.10.009","article-title":"Bioanalytical chemistry of cytokines--a review","volume":"853","author":"Stenken","year":"2015","journal-title":"Anal Chim Acta"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2025.101600_bib2","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical insights into cytokines","volume":"37","author":"Dinarello","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2843","article-title":"The colony-stimulating factors and cancer","volume":"10","author":"Metcalf","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2025.101600_bib4","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V78.11.2791.bloodjournal78112791","article-title":"Granulocyte colony-stimulating factor and its receptor","volume":"78","author":"Demetri","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","article-title":"Hematopoietic cytokines","volume":"111","author":"Metcalf","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib6","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.1500117","article-title":"Cytokines in graft-versus-host disease","volume":"194","author":"Henden","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib7","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","article-title":"Cytokine dysregulation and acute graft-versus-host disease","volume":"80","author":"Antin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib8","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.beha.2025.101600_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217814","article-title":"Investigation of the impact from IL-2, IL-7, and IL-15 on the growth and signaling of activated CD4(+) T cells","volume":"21","author":"Coppola","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2025.101600_bib12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self-renewal versus differentiation","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"10.1016\/j.beha.2025.101600_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.beha.2025.101600_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V95.1.19","article-title":"The Jak-Stat pathway in normal and perturbed hematopoiesis","volume":"95","author":"Ward","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101600_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/35049577","article-title":"Diversification of haematopoietic stem cells to specific lineages","volume":"1","author":"Orkin","year":"2000","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.beha.2025.101600_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81357-4","article-title":"From form to function: signaling by protein tyrosine phosphatases","volume":"87","author":"Tonks","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.beha.2025.101600_bib20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V68.5.1178.1178","article-title":"Autocrine secretion of GM-CSF in acute myeloblastic leukemia","volume":"68","author":"Young","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.leu.2404152","article-title":"Role of cytokines in the treatment of acute leukemias: a review","volume":"20","author":"Ravandi","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2025.101600_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071381","article-title":"Chronic lymphocytic leukemia (CLL)-Derived extracellular vesicles educate endothelial cells to become IL-6-producing, CLL-supportive cells","volume":"12","author":"Uziel","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.beha.2025.101600_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF02983377","article-title":"Survival and proliferation factors of normal and malignant plasma cells","volume":"78","author":"Klein","year":"2003","journal-title":"Int J Hematol"},{"key":"10.1016\/j.beha.2025.101600_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fmicb.2020.00356","article-title":"IL-2\/IL-2 receptor pathway plays a crucial role in the growth and malignant transformation of HTLV-1-infected T cells to develop adult T-cell leukemia","volume":"11","author":"Maeda","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.beha.2025.101600_bib25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2025.101600_bib26","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri2657","article-title":"Naive T cell homeostasis: from awareness of space to a sense of place","volume":"9","author":"Takada","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1600-065X.1997.tb00974.x","article-title":"Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy","volume":"157","author":"Mackall","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beha.2025.101600_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102164","article-title":"Lymphopenia-induced lymphoproliferation drives activation of naive T cells and expansion of regulatory populations","volume":"24","author":"Eldershaw","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.beha.2025.101600_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2017.07.005","article-title":"Interleukin-7 availability is maintained by a hematopoietic cytokine sink comprising innate lymphoid cells and T cells","volume":"47","author":"Martin","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2025.101600_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4049\/jimmunol.0804159","article-title":"Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy","volume":"184","author":"Condomines","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib32","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1189\/jlb.3A1216-520RR","article-title":"TGF-\u03b2 inhibits IL-7-induced proliferation in memory but not naive human CD4(+) T cells","volume":"102","author":"Nguyen","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.beha.2025.101600_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2025.101600_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib37","first-page":"95","article-title":"Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.beha.2025.101600_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.beha.2025.101600_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/ar2336","article-title":"The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors","volume":"9","author":"de Rham","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.beha.2025.101600_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.beha.2025.101600_bib41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib42","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2025.101600_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101600_bib45","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beha.2025.101600_bib46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.2019000952","article-title":"Cytokines and costimulation in acute graft-versus-host disease","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib47","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/cmi.2016.54","article-title":"IL-17A \u2260 Th17 in GvHD","volume":"15","author":"Wu","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.stemcr.2018.04.003","article-title":"CXCL12\/CXCR4 signaling enhances human PSC-derived hematopoietic progenitor function and overcomes early in vivo transplantation failure","volume":"10","author":"Reid","year":"2018","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.beha.2025.101600_bib50","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-Kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.beha.2025.101600_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055876","article-title":"Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning","volume":"8","author":"De Bock","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2025.101600_bib52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cytogfr.2014.07.011","article-title":"G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent","volume":"25","author":"Bendall","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.beha.2025.101600_bib53","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1200\/JCO.2006.06.1663","article-title":"Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation","volume":"24","author":"Dekker","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib54","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.bbmt.2020.08.013","article-title":"The effect of granulocyte colony-stimulating factor use on hospital length of stay after allogeneic hematopoietic cell transplantation: a retrospective multicenter cohort study","volume":"26","author":"George","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001696","article-title":"Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD","volume":"135","author":"Piper","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib57","series-title":"The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies [Internet]","article-title":"Graft failure","author":"Valc\u00e1rcel","year":"2019"},{"key":"10.1016\/j.beha.2025.101600_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4274\/balkanmedj.galenos.2022.2022-2-48","article-title":"Eltrombopag for the treatment of poor graft function following haematopoietic cell transplantation: real-life data","volume":"40","author":"K\u0131rcal\u0131","year":"2023","journal-title":"Balkan Med J"},{"key":"10.1016\/j.beha.2025.101600_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2280872","article-title":"Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar","volume":"28","author":"Al-Mashdali","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.beha.2025.101600_bib61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V76.4.666.666","article-title":"Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure","volume":"76","author":"Ganser","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112736","article-title":"IL3 has a detrimental effect on hematopoietic stem cell self-renewal in transplantation settings","volume":"23","author":"Tajer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2025.101600_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.039","article-title":"Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells","volume":"185","author":"Omer-Javed","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.beha.2025.101600_bib64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/bmb\/ldad017","article-title":"Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation","volume":"147","author":"Canarutto","year":"2023","journal-title":"Br Med Bull"},{"key":"10.1016\/j.beha.2025.101600_bib65","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.V98.7.2256","article-title":"Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease","volume":"98","author":"Alpdogan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib66","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sport\u00e8s","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2025.101600_bib67","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2002-04-1082","article-title":"Interleukin 7 worsens graft-versus-host disease","volume":"100","author":"Sinha","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/bmt.2013.47","article-title":"Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT","volume":"48","author":"Sauter","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib69","doi-asserted-by":"crossref","first-page":"44366","DOI":"10.18632\/oncotarget.17875","article-title":"New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity","volume":"8","author":"Bailey","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.beha.2025.101600_bib70","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib71","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib72","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib73","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","article-title":"IL-2, regulatory T cells, and tolerance","volume":"172","author":"Nelson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib75","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib77","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib78","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib79","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2025.101600_bib80","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib81","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib82","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101600_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib85","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2025.101600_bib87","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with Refractory,Aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib88","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib89","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib90","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101600_bib92","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib93","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2025.101600_bib94","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2025.101600_bib95","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib96","doi-asserted-by":"crossref","first-page":"515.e1","DOI":"10.1016\/j.jtct.2023.05.008","article-title":"Tocilizumab for cytokine release syndrome management after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"29","author":"Yao","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101600_bib97","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 monoclonal antibody) in patients with multicentric castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101600_bib98","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","article-title":"The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T-cell associated toxicities","volume":"58","author":"Gutierrez","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.beha.2025.101600_bib99","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2025.101600_bib100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101600_bib101","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101600_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101600_bib103","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib104","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib106","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib107","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","article-title":"Myeloma CAR-T CRS management with IL-1R antagonist anakinra","volume":"20","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2025.101600_bib108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/08880018.2021.1988012","article-title":"Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults","volume":"39","author":"Dreyzin","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib109","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2021-147454","article-title":"Safety and efficacy of two anakinra dose regimens for refractory CRS or icans after CAR T-cell therapy","volume":"138","author":"Gazeau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib110","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1200\/JCO.2021.39.15_suppl.7566","article-title":"IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome","volume":"39","author":"Oliai","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib111","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1182\/blood-2022-157448","article-title":"Primary analysis of a pilot study of prophylactic anakinra to mitigate CAR T cell-associated toxicity in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib113","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2025.101600_bib115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.beha.2025.101600_bib116","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.beha.2025.101600_bib117","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.beha.2025.101600_bib118","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.beha.2025.101600_bib119","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib121","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib122","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.beha.2025.101600_bib123","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"Diagnosis and management of acute graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib125","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib126","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib127","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.beha.2025.101600_bib128","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib129","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib130","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2025.101600_bib131","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib132","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib133","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2020007336","article-title":"Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness","volume":"136","author":"Mohty","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib134","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.17700","article-title":"Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis","volume":"195","author":"Abedin","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2025.101600_bib136","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib137","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2025.101600_bib138","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","volume":"193","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101600_bib139","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beha.2025.101600_bib140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib141","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101600_bib142","first-page":"1234","article-title":"Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation","volume":"25","author":"Holler","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1016\/j.beha.2025.101600_bib143","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V75.4.1011.1011","article-title":"Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation","volume":"75","author":"Holler","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib144","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2009.05.019","article-title":"Infliximab for managing steroid-refractory acute graft-versus-host disease","volume":"15","author":"Pidala","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib145","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41409-018-0099-3","article-title":"Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival","volume":"53","author":"Nygaard","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib146","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/tri.13601","article-title":"Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations","volume":"33","author":"Lawitschka","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.beha.2025.101600_bib147","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.jtct.2022.06.008","article-title":"Clinical features, treatment, and outcome of pediatric steroid refractory acute graft-versus-host disease: a multicenter study","volume":"28","author":"Verbeek","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2025.101600_bib148","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705761","article-title":"Infliximab for GVHD therapy in children","volume":"40","author":"Sleight","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib149","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1399-3046.2012.01756.x","article-title":"Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Yang","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143605","article-title":"Advantage of first-line therapeutic drug monitoring-driven use of infliximab for treating acute intestinal and liver GVHD in children: a prospective, single-center study","volume":"15","author":"Maximova","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.beha.2025.101600_bib151","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3727\/096368912X653110","article-title":"Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation","volume":"21","author":"Lai","year":"2012","journal-title":"Cell Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib152","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood.V96.9.2973","article-title":"T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease","volume":"96","author":"Serody","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib153","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1703563","article-title":"T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease","volume":"29","author":"New","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib154","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/mi.2015.61","article-title":"Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10","volume":"9","author":"Lamarth\u00e9e","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.beha.2025.101600_bib155","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2006-12-061408","article-title":"CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation","volume":"110","author":"Piper","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib156","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.1074\/jbc.M110.214965","article-title":"Interleukin-13 (IL-13)\/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion","volume":"286","author":"Wu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2025.101600_bib157","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/bmt.2010.13","article-title":"Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse","volume":"45","author":"Thiant","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252995","article-title":"A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant","volume":"16","author":"Ramalingam","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2025.101600_bib159","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/434010","article-title":"Cytokine levels in the serum of healthy subjects","volume":"2013","author":"Kleiner","year":"2013","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.beha.2025.101600_bib160","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","article-title":"Tumor necrosis factor-alpha blockade for the treatment of acute GVHD","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib161","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1703094","article-title":"Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human\/mouse antiTNFalpha antibody","volume":"28","author":"Kobbe","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib162","first-page":"1352","article-title":"Infliximab treatment for steroid-refractory acute graft-versus-host disease","volume":"89","author":"Patriarca","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2025.101600_bib163","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1590\/S0100-879X2006005000145","article-title":"Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease","volume":"40","author":"Nogueira","year":"2007","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.beha.2025.101600_bib164","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.bbmt.2017.05.001","article-title":"Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease","volume":"23","author":"Yalniz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib165","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib166","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bbmt.2005.05.009","article-title":"Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease","volume":"11","author":"Uberti","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib167","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2007-09-112987","article-title":"Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease","volume":"111","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib168","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbmt.2009.08.003","article-title":"A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease","volume":"15","author":"Couriel","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib169","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbmt.2014.05.023","article-title":"Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"20","author":"Gatza","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101600_bib170","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ebiom.2019.02.001","article-title":"Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model","volume":"41","author":"Ono","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.beha.2025.101600_bib171","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1172\/JCI133909","article-title":"Donor monocyte-derived macrophages promote human acute graft-versus-host disease","volume":"130","author":"Jardine","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101600_bib172","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101600_bib173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101600_bib174","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101600_bib175","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:23:11Z","timestamp":1741609391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":175,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1521692625000052"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101600","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines in hematopoietic cell transplantation and related cellular therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101600"}}